The North America Adenosine Triphosphate (ATP) swab test market is expected to reach US$ 132.91 million by 2027 from US$ 69.83 million in 2019. The market is estimated to grow at a CAGR of 8.4% from 2020 to 2027. The growth of the market is attributed to the key driving factors such as rising prevalence of healthcare associated infections (HAI) and increasing emphasis on food safety. However, the limitations of ATP swab tests hinder the market growth.
The ATP Swab test is a fast calculation by identification of adenosine triphosphate or ATP of aggressively developing microorganisms.ATP is a molecule in and near living cells that explicitly tests the organisms’ biological production and well-being.
Healthcare-associated infectious (HAI) are caused while receiving treatments or therapies in healthcare facilities.These infections are related to surgical procedures and medical instruments used during operations.
The rising prevalence of HAIs is one of the prominent factors driving the demand for ATP swab tests.For instance, according to a study published by the Centers for Disease Control and Prevention (CDC) in 2019, an estimated 1 in 31 hospital patients has some healthcare-associated infection (HAI) across the globe.
Such a substantial prevalence of healthcare-associated disorders propels the adoption of the ATP swab test. Also, the utilization of adenosine triphosphate is a major indicator of cleanliness and sterilization in food & beverages. Hence, the rising incidence of foodborne diseases and food contamination is prominently expected to drive the growth of the North America Adenosine Triphosphate (ATP) swab test market during the forecast period.
The COVID-19 outbreak pandemic is adversely affecting countries in North America.In the US, all sanitization processes at hospitals, medical establishments, and high touch point surfaces in public places utilize Adenosine Triphosphate (ATP) Swab Test to confirm the surface is free from microorganisms, which boosts the growth of the North America Adenosine Triphosphate (ATP) swab test market.
However, the growing number of COVID-19 confirmed cases has resulted in disruption in the supply chain due to a long period of lockdown, which hampers the market growth.
The North America Adenosine Triphosphate (ATP) Swab Test market, based on type, is segmented into free ATP test and microbial ATP test. In 2019, the microbial ATP test segment held a larger market share, and the market for the same segment is expected to grow at a faster rate during the coming years.
The North America Adenosine Triphosphate (ATP) Swab Test market, based on the application, is segmented into pharmaceutical & biotechnology company, food & beverage, hospitals & diagnostics laboratories, and academic & research institutions.In 2019, the pharmaceutical & biotechnology company segment held the largest share of the market.
Moreover, the market for the same segment is expected to grow at the fastest rate during the coming years.
A few of the primary and secondary sources referred to while preparing the report on the North America Adenosine Triphosphate (ATP) swab test market are the American Society of Testing and Material (ASTM), Centers for Disease Control and Prevention (CDC), and World Health organization (WHO).
Our reports have been used by over 10K customers, including:
Executive Summary The mRNA technology finds its applications in many diseases including the Covid-19 vaccine. The market for mRNA is mostly driven by the Covid-19 vaccine besides its major usage in cancer therapies. With the mutation of the coronavirus and possible spread of variants of the virus, the mRNA companies are...
“Dopamine D2 receptor antagonists– Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dopamine D2 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product...
Phenylketonuria (PKU) (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria - Drugs in Development, 2021, provides an overview of the Phenylketonuria (Metabolic Disorders) pipeline landscape. Phenylketonuria...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The peptide therapeutics market was valued at US$ 24,878.55 million in 2019 and is projected to reach US$ 50,003.15 million by 2027; it is expected to grow at a CAGR of 9.2% during 2020–2027. The growth of the peptide therapeutics market is mainly attributed to the growing investments on peptide therapeutics and increasing prevalence of metabolic...
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The growth of this market is driven owing to the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing...
The North America Digital Therapeutics Market would witness market growth of 20.9% CAGR during the forecast period (2021-2027). Digital Therapeutics is used through various digital platforms such as internet-based health technologies to supervise all the changes that occur in patient conditions. Mainly, digital treatment aims to monitor...
The Multiple Sclerosis Therapeutics market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027. The growth of the multiple sclerosis therapeutics market is mainly attributed to factors, such as growing prevalence of multiple...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.